• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Revelation Biosciences Inc.

    2/21/23 4:49:56 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REVB alert in real time by email
    SC 13G 1 schedule13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
         
         
         
     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No.   )*
     
         
     
    Revelation Biosciences, Inc.
     
     
    (Name of Issuer)
     
         
     
    Common Stock, par value $0.001 per share
     
     
    (Title of Class of Securities)
     

     
    76135L309
     
     
    (CUSIP Number)
     

     
    February 13, 2023
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [ ]
    Rule 13d-1(b)
     
    [x]
    Rule 13d-1(c)
     
    [ ]
    Rule 13d-1(d)
     






    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Fund II LP

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    186,500
    6 Shared Voting Power
     
    0
    7 Sole Dispositive Power
     
    186,500
    8 Shared Dispositive Power
     
    0
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    186,500(1)
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    5.2%(2)
    12
    Type of Reporting Person (See Instructions)

    PN
    (1) The reporting person’s ownership consists of (i) 186,500 shares of common stock and (ii) 373,000 warrants to purchase shares of common stock (“Warrants”); however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership of the Warrants is excluded.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 4.99% of the Company.
     

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Partners II LLC

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    186,500
    6 Shared Voting Power
     
    0
    7 Sole Dispositive Power
     
    186,500
    8 Shared Dispositive Power
     
    0
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    186,500(1)
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    5.2%(2)
    12
    Type of Reporting Person (See Instructions)

    OO
    (1) The reporting person’s ownership consists of (i) 186,500 shares of common stock and (ii) 373,000 Warrants; however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership of the Warrants is excluded.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 4.99% of the Company.


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    186,500
    6 Shared Voting Power
     
    0
    7 Sole Dispositive Power
     
    186,500
    8 Shared Dispositive Power
     
    0
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
    186,500(1)
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    5.2%(2)
    12
    Type of Reporting Person (See Instructions)
     
    IN
    (1) The reporting person’s ownership consists of (i) 186,500 shares of common stock and (ii) 373,000 Warrants; however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership of the Warrants is excluded.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 4.99% of the Company.


    Item 1.
     
     
    (a)
    Name of Issuer
       
     
    Revelation Biosciences, Inc.
     
    (b)
    Address of Issuer’s Principal Executive Offices
       
     
    4660 La Jolla Village Drive
    Suite 100
    San Diego, California 92122
     

    Item 2.
     
     
    (a)
    Name of Person Filing
       
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    • Lind Global Fund II LP, a Delaware limited partnership;
    • Lind Global Partners II LLC, a Delaware limited liability company; and
    • Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
     
    (b)
    Address of Principal Business Office or, if none, Residence
       
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
     
    (c)
    Citizenship
       
     
    See Row 4 of cover page for each Reporting Person.
     
     
    (d)
    Title of Class of Securities
         
       
    Common Stock, par value $0.001 per share
         
     
    (e)
    CUSIP Number
       
     
    76135L309
     

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
    Not applicable.
     
    Item 4.
    Ownership
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
     
    (a)
    Amount Beneficially Owned
       
     
     See Row 9 of cover page for each Reporting Person.
     
     
    (b)
    Percent of Class
       
     
    See Row 11 of cover page for each Reporting Person.
     

     
    (c)
    Number of shares as to which such person has:
     
       
    (i)
    sole power to vote or to direct the vote
         

    See Row 5 of cover page for each Reporting Person.
     
       
    (ii)
    shared power to vote or to direct the vote
         
     
    See Row 6 of cover page for each Reporting Person.
     
       
    (iii)
    sole power to dispose or to direct the disposition of
         

    See Row 7 of cover page for each Reporting Person.
     
       
    (iv)
    shared power to dispose or to direct the disposition of
         
     
    See Row 8 of cover page for each Reporting Person.
     
     

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.


    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group

    Not applicable.
     
    Item 9.
    Notice of Dissolution of Group

    Not applicable.
     
    Item 10.
    Certification
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits
    Exhibit
     
    99.1               Joint Filing Agreement by and among the Reporting Persons.
     


    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    February 21, 2023
     
    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton

    Get the next $REVB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $REVB

    DatePrice TargetRatingAnalyst
    2/17/2022$12.00Buy
    Roth Capital
    More analyst ratings

    $REVB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

      – Sample analysis and data collection ongoing – – Data expected during Q3 2025 – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced dosing has been completed for the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). As planned, a total of 5 cohorts were enrolled at 3 clinics in the United States. Several study data sets are expected during Q3 2025: these will include safety parameters, changes in hematologic pa

      7/16/25 9:00:00 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of its common stock following approval at its Special Meeting of Stockholders held on June 23, 2025. The reverse stock split will be effective as of the morning of July 7, 2025, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol "REVB." The CUSIP number for the common stock following the reverse stock split will be 76135L705. The reverse stock split is intended to increase the market price per share of the Company's common stock to reg

      7/1/25 5:26:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years

      5/29/25 4:05:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chawla Lakhmir S was granted 181 shares (SEC Form 4)

      4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

      2/13/25 6:14:40 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Carver Jennifer was granted 181 shares, increasing direct ownership by 3,017% to 187 units (SEC Form 4)

      4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

      2/13/25 6:12:17 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Roper Jess was granted 181 shares, increasing direct ownership by 9,050% to 183 units (SEC Form 4)

      4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

      2/13/25 6:09:20 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    SEC Filings

    See more
    • Revelation Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      7/9/25 4:17:31 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      6/25/25 4:26:46 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Revelation Biosciences Inc.

      DEF 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      6/9/25 4:51:25 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on Revelation Biosciences with a new price target

      Roth Capital initiated coverage of Revelation Biosciences with a rating of Buy and set a new price target of $12.00

      2/17/22 8:17:25 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Financials

    Live finance-specific insights

    See more
    • Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights Announced a new indication for Gemini in severe burn patients Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells Completed dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients "While we continue to expand the pipeline here at Revelation, we are excited to continue our collaboration with Vanderbilt and Dr. Bohannon in the area of severe bu

      5/8/25 4:15:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FDA Acceptance of Gemini IND Received net proceeds of $3.7 million from the exercise of warrants in December 2024 "We made significant progress at the end of last year and hope to continue that pace in 2025," said James

      3/6/25 4:15:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Received net proceeds of $3.8 million from the exercise of warrants in August 2024 Announced Gemini induces dose dependent significant increases in IL-10 in healthy volunteers "The Revelation team continues to make significan

      11/8/24 4:15:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Leadership Updates

    Live Leadership Updates

    See more
    • Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

      5/23/25 4:05:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

      – A vote for Proposal 2 saves the Company over $200,000 per year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franchise tax fees. All proposals in the proxy are important and the Board of Directors has suggested a vote for all proposals. Please vote by calling Advantage Pr

      1/13/25 6:00:00 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

      Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company's Board of Directors (Board). "We are excited to welcome Dr. Chawla as an independent director to our Board," said James Rolke, Chief Executive Officer of Revelation. "Dr. Chawla brings decades of expertise and leadership in key areas such as nephrology, critical care medicine, drug development and strategic implementation. I am confident that he will provide valuable perspectives as we continue to execute our str

      10/2/23 9:00:00 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Revelation Biosciences Inc. (Amendment)

      SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

      2/13/24 8:12:05 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Revelation Biosciences Inc.

      SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

      1/3/24 8:36:37 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Revelation Biosciences Inc.

      SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

      2/21/23 4:49:56 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care